Liquid biopsy in breast cancer: A comprehensive review
- PMID: 30671931
- DOI: 10.1111/cge.13514
Liquid biopsy in breast cancer: A comprehensive review
Abstract
Breast cancer is the most common cancer among women worldwide. Due to its complexity in nature, effective breast cancer treatment can encounter many challenges. Traditional methods of cancer detection such as tissue biopsy are not comprehensive enough to capture the entire genomic landscape of breast tumors. However, with the introduction of novel techniques, the application of liquid biopsy has been enhanced, enabling the improvement of various aspects of breast cancer management including early diagnosis and screening, prediction of prognosis, early detection of relapse, serial sampling and efficient longitudinal monitoring of disease progress and response to treatment. Various components of tumor cells released into the blood circulation can be analyzed in liquid biopsy sampling, some of which include circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free RNA, tumor-educated platelets and exosomes. These components can be utilized for different purposes. As an example, ctDNA can be sequenced for genetic profiling of the tumors to enhance individualized treatment and longitudinal screening. CTC plasma count analysis or ctDNA detection after curative tumor resection surgery could facilitate early detection of minimal residual disease, aiding in the initiation of adjuvant therapy to prevent recurrence. Furthermore, CTC plasma count can be assessed to determine the stage and prognosis of breast cancer. In this review, we discuss the advantages and limitations of the various components of liquid biopsy used in breast cancer diagnosis and will expand on aspects that require further focus in future research.
Keywords: breast cancer; cfDNA; circulating tumor cell; ctDNA; liquid biopsy.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
Liquid biopsy: current technology and clinical applications.J Hematol Oncol. 2022 Sep 12;15(1):131. doi: 10.1186/s13045-022-01351-y. J Hematol Oncol. 2022. PMID: 36096847 Free PMC article. Review.
-
ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment.Clin Cancer Res. 2018 Mar 15;24(6):1500-1510. doi: 10.1158/1078-0432.CCR-17-1181. Epub 2017 Dec 28. Clin Cancer Res. 2018. PMID: 29284708
-
Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?Cancer Lett. 2020 Jan 1;468:59-71. doi: 10.1016/j.canlet.2019.10.014. Epub 2019 Oct 11. Cancer Lett. 2020. PMID: 31610267 Review.
-
Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer.Int J Mol Sci. 2022 Sep 1;23(17):9952. doi: 10.3390/ijms23179952. Int J Mol Sci. 2022. PMID: 36077348 Free PMC article. Review.
-
Liquid biopsy and their application progress in head and neck cancer: focus on biomarkers CTCs, cfDNA, ctDNA and EVs.Biomark Med. 2020 Oct;14(14):1393-1404. doi: 10.2217/bmm-2020-0022. Epub 2020 Oct 19. Biomark Med. 2020. PMID: 33073579 Review.
Cited by
-
Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer.Cancer Biol Ther. 2024 Dec 31;25(1):2405060. doi: 10.1080/15384047.2024.2405060. Epub 2024 Sep 20. Cancer Biol Ther. 2024. PMID: 39304993 Free PMC article. Review.
-
Emerging Cancer Epigenetic Mechanisms Regulated by All-Trans Retinoic Acid.Cancers (Basel). 2020 Aug 14;12(8):2275. doi: 10.3390/cancers12082275. Cancers (Basel). 2020. PMID: 32823855 Free PMC article. Review.
-
Potential utility of miRNAs for liquid biopsy in breast cancer.Front Oncol. 2022 Aug 4;12:940314. doi: 10.3389/fonc.2022.940314. eCollection 2022. Front Oncol. 2022. PMID: 35992785 Free PMC article. Review.
-
Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics.Cancers (Basel). 2023 Aug 3;15(15):3949. doi: 10.3390/cancers15153949. Cancers (Basel). 2023. PMID: 37568766 Free PMC article.
-
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.Breast Cancer Res. 2023 Oct 2;25(1):112. doi: 10.1186/s13058-023-01718-0. Breast Cancer Res. 2023. PMID: 37784176 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials